GILD

Gilead Sciences, Inc. [GILD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

GILD Stock Summary

Top 10 Correlated Stocks

GILD


In the News

06:45 29 Mar 2024 GILD

7 Value Stocks to Buy at a 52-Week Low in March

When it comes to finding the best value stocks to buy, sometimes you have to go against the grain. That is, dive into stocks that have fallen out of favor with the market, to assess whether investor sentiment is on the money, or an overreaction.

04:43 29 Mar 2024 GILD

Gilead Sciences Finally Starts Succeeding

Gilead Sciences has a strong track record in curing Hepatitis C and a successful HIV business. The company has struggled with acquisitions but is expected to generate strong shareholder returns. Gilead Sciences has new businesses and milestones planned for 2024.

10:05 29 Mar 2024 GILD

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

07:05 29 Mar 2024 GILD

Gilead Sciences (GILD) Rises But Trails Market: What Investors Should Know

Gilead Sciences (GILD) reachead $73.41 at the closing of the latest trading day, reflecting a +0.2% change compared to its last close.

08:15 29 Mar 2024 GILD

2 Top Dividend Stocks to Buy Hand Over Fist

AbbVie and Gilead Sciences haven't been recording excellent financial results lately. But both drugmakers have solid lineups and pipelines that should allow them to recover.

06:04 29 Mar 2024 GILD

Gilead CAR-T cancer therapy capacity to quadruple by 2026

Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech's manufacturing processes, an executive in charge of that business told Reuters.

07:06 29 Mar 2024 GILD

Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know

Gilead Sciences (GILD) closed the most recent trading day at $75.94, moving +1.15% from the previous trading session.

08:26 29 Mar 2024 GILD

Gilead Sciences, Inc. (GILD) Leerink Partners Global Biopharma Conference (Transcript)

Gilead Sciences, Inc. (GILD) Leerink Partners Global Biopharma Conference (Transcript)

11:48 29 Mar 2024 GILD

39 Upcoming Dividend Increases Including 2 Dividend Kings

Thirty-nine companies, including Coca-Cola and Telephone and Data Systems, are raising their dividends.

06:55 29 Mar 2024 GILD

Why Gilead Sciences (GILD) Outpaced the Stock Market Today

In the most recent trading session, Gilead Sciences (GILD) closed at $73.66, indicating a +1.42% shift from the previous trading day.

GILD Financial details

Company Rating
Strong Buy
Market Cap
90.46B
Income
5.66B
Revenue
27.12B
Book val./share
18.23
Cash/share
5.82
Dividend
3.02
Dividend %
4.14%
Employees
18K
Optionable
Yes
Shortable
Yes
Earnings
25 Apr 2024
P/E
16.09
Forward P/E
13.2
PEG
6.69
P/S
3.35
P/B
4.01
P/C
12.59
P/FCF
12.26
Quick Ratio
1.06
Current Ratio
1.46
Debt / Equity
1.1
LT Debt / Equity
1.02
-
-
EPS (TTM)
4.54
EPS next Y
5.55
EPS next Q
1.58
EPS this Y
24.04%
EPS next Y
22.27%
EPS next 5Y
93.18%
EPS last 5Y
1.38%
Revenue last 5Y
3.85%
Revenue Q/Q
0.92%
EPS Q/Q
-34.86%
-
-
-
-
SMA20
-
SMA50
-14.12%
SMA100
-8.75%
Inst Own
71.09%
Inst Trans
0.87%
ROA
9%
ROE
26%
ROC
0.17%
Gross Margin
78%
Oper. Margin
31%
Profit Margin
21%
Payout
67%
Shs Outstand
1.25B
Shs Float
1.24B
-
-
-
-
Target Price
79.25
52W Range
71.37-87.87
52W High
-15.8%
52W Low
+3.17%
RSI
48
Rel Volume
1.12
Avg Volume
7.38M
Volume
8.24M
Perf Week
0.22%
Perf Month
2.33%
Perf Quarter
-2.41%
Perf Half Y
-3.02%
-
-
-
-
Beta
0.2
-
-
Volatility
0.34%, 0.96%
Prev Close
0%
Price
73.25
Change
0%

GILD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
17.6819.6421.7421.7421.73
Net income per share
4.240.074.963.664.54
Operating cash flow per share
7.26.59.067.236.42
Free cash flow per share
6.555.988.66.655.95
Cash per share
19.175.895.195.095.82
Book value per share
17.8314.516.7716.918.23
Tangible book value per share
3.74-18.31-16.5-12.75-9.63
Share holders equity per share
17.8314.516.7716.918.23
Interest debt per share
20.1525.7622.0520.8520.78
Market cap
82.52B73.23B91.2B107.74B101.1B
Enterprise value
95.49B98.64B112.56B127.56B120B
P/E ratio
15.32822.8414.6523.4617.85
Price to sales ratio
3.682.973.343.953.73
POCF ratio
9.038.978.0111.8812.63
PFCF ratio
9.929.748.4412.9113.62
P/B Ratio
3.644.024.335.084.44
PTB ratio
3.644.024.335.084.44
EV to sales
4.2544.124.684.43
Enterprise value over EBITDA
15.5111.5911.912.2710.26
EV to operating cash flow
10.4412.089.8914.0614.99
EV to free cash flow
11.4813.1210.4215.2916.17
Earnings yield
0.0700.070.040.06
Free cash flow yield
0.10.10.120.080.07
Debt to equity
1.091.721.271.191.1
Debt to assets
0.40.460.390.40.4
Net debt to EBITDA
2.112.992.261.911.62
Current ratio
3.231.391.31.361.46
Interest coverage
4.317.147.47.849.92
Income quality
1.791.781.841.991.43
Dividend Yield
0.040.050.040.030.04
Payout ratio
0.638.750.580.810.67
Sales general and administrative to revenue
0.160.180.170.180
Research and developement to revenue
0.410.20.20.180.21
Intangibles to total assets
0.290.60.610.590.56
Capex to operating cash flow
-0.09-0.08-0.05-0.08-0.07
Capex to revenue
-0.04-0.03-0.02-0.03-0.02
Capex to depreciation
-0.59-0.44-0.28-0.35-0.22
Stock based compensation to revenue
0.030.030.020.020.03
Graham number
41.254.8143.2537.343.15
ROIC
0.090.010.110.120.16
Return on tangible assets
0.1200.240.180.21
Graham Net
-8.59-29.91-28.37-24.37-21.58
Working capital
21.73B4.42B3.45B3.99B5.17B
Tangible asset value
4.75B-23.01B-20.72B-16B-12.02B
Net current asset value
-7.49B-34.37B-31.83B-26.74B-22.92B
Invested capital
1.091.721.271.191.1
Average receivables
3.45B4.24B4.69B4.64B4.72B
Average payables
751.5M778.5M774.5M805M727.5M
Average inventory
1.44B2.54B2.87B2.78B3.09B
Days sales outstanding
58.2472.3260.0663.9162.73
Days payables outstanding
55.6767.3838.9858.3933.64
Days of inventory on hand
161.38240.62151.18181.95205.86
Receivables turnover
6.275.056.085.715.82
Payables turnover
6.565.429.366.2510.85
Inventory turnover
2.261.522.412.011.77
ROE
0.2400.30.220.25
Capex per share
-0.65-0.52-0.46-0.58-0.47

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
5.95.095.285.655.7
Net income per share
1.310.810.841.751.15
Operating cash flow per share
2.051.41.871.411.74
Free cash flow per share
1.91.311.761.311.57
Cash per share
5.14.7110.975.55.82
Book value per share
16.9416.7816.8917.8218.23
Tangible book value per share
-12.78-12.6-11.99-10.6-9.63
Share holders equity per share
16.9416.7816.8917.8218.23
Interest debt per share
20.3321.4321.4820.9420.22
Market cap
107.48B103.55B96.26B93.53B101.1B
Enterprise value
127.3B125.13B117.16B113.73B120B
P/E ratio
16.3825.6323.0310.7317.69
Price to sales ratio
14.5516.314.5913.2714.21
POCF ratio
41.8959.3741.1953.2646.61
PFCF ratio
45.0763.3343.7957.2451.74
P/B Ratio
5.074.954.564.24.44
PTB ratio
5.074.954.564.24.44
EV to sales
17.2319.717.7516.1316.87
Enterprise value over EBITDA
52.6962.2257.0443.0638.23
EV to operating cash flow
49.6171.7550.1364.7655.33
EV to free cash flow
53.3876.5353.369.661.41
Earnings yield
0.020.010.010.020.01
Free cash flow yield
0.020.020.020.020.02
Debt to equity
1.191.271.261.161.1
Debt to assets
0.40.430.430.420.4
Net debt to EBITDA
8.210.7310.177.656.02
Current ratio
1.361.371.11.341.46
Interest coverage
9.997.417.2411.319.94
Income quality
1.571.772.250.811.53
Dividend Yield
0.010.010.010.010.01
Payout ratio
0.560.960.90.440.66
Sales general and administrative to revenue
0.170000
Research and developement to revenue
0.210.230.210.210.2
Intangibles to total assets
0.590.590.580.570.56
Capex to operating cash flow
-0.07-0.06-0.06-0.07-0.1
Capex to revenue
-0.02-0.02-0.02-0.02-0.03
Capex to depreciation
-0.34-1.16-0.2-0.18-0.31
Stock based compensation to revenue
0.020.030.030.030.03
Graham number
22.3417.4817.8326.4721.67
ROIC
0.040.030.020.050.04
Return on tangible assets
0.060.040.040.080.05
Graham Net
-24.43-24.39-18.24-22.49-21.58
Working capital
3.99B3.84B1.45B4.07B5.17B
Tangible asset value
-16B-15.72B-14.97B-13.22B-12.02B
Net current asset value
-26.74B-26.57B-25.83B-24.12B-22.92B
Invested capital
1.191.271.261.161.1
Average receivables
4.57B4.47B4.2B4.51B4.73B
Average payables
759.5M766M624.5M604M568M
Average inventory
2.71B2.92B3.1B3.19B3.28B
Days sales outstanding
58.1958.9757.6861.1558.95
Days payables outstanding
58.3540.2838.8233.731.73
Days of inventory on hand
181.81193.36198.54184.14194.19
Receivables turnover
1.551.531.561.471.53
Payables turnover
1.542.232.322.672.84
Inventory turnover
0.50.470.450.490.46
ROE
0.080.050.050.10.06
Capex per share
-0.14-0.09-0.11-0.1-0.17

GILD Frequently Asked Questions

What is Gilead Sciences, Inc. stock symbol ?

Gilead Sciences, Inc. is a US stock , located in Foster city of Ca and trading under the symbol GILD

Is Gilead Sciences, Inc. buy or a sell ?

30 stock analysts have 30 predictions with a medium analyst target price of $76.57. The lowest prediction is $54 and the highest is $112

What is GILD stock prediction ?

With a median analyst target price of $76, 1 stock analysts have made 1 forecasts in last 90 days. $76 is the lowest and $76 is the greatest projection.

What is Gilead Sciences, Inc. stock quote today ?

Gilead Sciences, Inc. stock price is $73.25 today.

Is Gilead Sciences, Inc. stock public?

Yes, Gilead Sciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap